Drug Interactions between Pepcid and zafirlukast
This report displays the potential drug interactions for the following 2 drugs:
- Pepcid (famotidine)
- zafirlukast
Interactions between your drugs
No interactions were found between Pepcid and zafirlukast. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Pepcid
A total of 313 drugs are known to interact with Pepcid.
- Pepcid is in the drug class H2 antagonists.
- Pepcid is used to treat the following conditions:
zafirlukast
A total of 300 drugs are known to interact with zafirlukast.
- Zafirlukast is in the drug class leukotriene modifiers.
- Zafirlukast is used to treat Asthma, Maintenance.
Drug and food interactions
zafirlukast food
Applies to: zafirlukast
ADJUST DOSING INTERVAL: Food may reduce the oral absorption and bioavailability of zafirlukast. In two separate studies, one using a high-fat and the other a high-protein meal, administration of zafirlukast with food reduced the mean bioavailability by approximately 40%.
MANAGEMENT: To ensure maximal oral absorption, zafirlukast should be administered at least 1 hour before or 2 hours after meals.
References (1)
- (2001) "Product Information. Accolate (zafirlukast)." Astra-Zeneca Pharmaceuticals
famotidine food
Applies to: Pepcid (famotidine)
H2 antagonists may reduce the clearance of nicotine. Cimetidine, 600 mg given twice a day for two days, reduced clearance of an intravenous nicotine dose by 30%. Ranitidine, 300 mg given twice a day for two days, reduced clearance by 10%. The clinical significance of this interaction is not known. Patients should be monitored for increased nicotine effects when using the patches or gum for smoking cessation and dosage adjustments should be made as appropriate.
References (1)
- Bendayan R, Sullivan JT, Shaw C, Frecker RC, Sellers EM (1990) "Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans." Eur J Clin Pharmacol, 38, p. 165-9
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.